Introduction
Breast cancer (BC) is the most frequently diagnosed cancer, as well as, the leading cause of death in the female population [1] . Triple negative breast cancer (TNBC) accounts for 12-20% of all BCs and, in this phenotype of BC, cells lack the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2/neu) [2, 3] . Drug-resistant TNBCs metastasise rapidly, have poor prognosis which renders them extremely difficult to treat and, they also appear to be occurring more frequently in younger women [3, 4] .
Therefore, it is crucial to develop and test new, selective and efficient anti-cancer drugs that counteract TNBC cell growth, but also limit side effects which are often unmanageable for patients.
Chemotherapy, using a broad spectrum of cytotoxic drugs, such as, doxorubicin, daunorubicin, or epirubicin, is the primary treatment offered to TNBC patients. The therapeutic use of these drugs relies on their ability to interact and target DNA by intercalation [5] thus, interfering with transcription and/or replication.
Notably, this mode of action remains the most effective treatment for, not only breast cancer, but also acute leukaemia, ovarian and bladder cancers [6] .
Bisnaphthalimides constitute a promising group of anti-cancer compounds which target DNA by intercalation and have strong cytotoxic properties observed in vitro [7, 8, 9] . Typically, these compounds consist of two naphthalamidochromophore units linked by alkyl chains containing at least one amino group [10] .
Noteworthy examples are Elinafide (LU79553) [11, 12] and Bisnafide (DMP-840) [13] which progressed to Phase I and II clinical trials for advanced solid cancers.
Despite encouraging preliminary anti-tumour activities, problems with efficacy and adverse dose-limiting toxicities, for example, myelosuppression [11, 13] and neuromuscular toxicity [12] of a cumulative nature were observed. To address such issues, more research is required in order to improve where these former bisnaphthalimide derivatives have clinically failed.
For a number of years, our research group have been designing and synthesising bisnaphthalimidopropyl (BNIP) derivatives linked to natural polyamines [14, 15, 16] , and to a selection of diamino and triamino alkyl chains [17, 18, 19, 20] which have enhanced aqueous solubility and strong DNA-binding affinities. BNIP derivatives were found to be more cytotoxic (IC50 values in the range of 4.9-12.7 µM) than the chemotherapy drug doxorubicin (IC50 value 14.4 µM) in breast cancer MDA-MB-231 cells, after 24 hours [20] . Moreover, BNIP derivatives were less cytotoxic in non-tumourigenic breast epithelial MCF-10A cells than doxorubicin; which gave an indication of the selectivity of BNIP derivatives in both cancerous and surrounding healthy tissues [20] .
DNA was suggested to be a potential target for BNIP derivatives by Barron et al. [20] ; however, the specific mechanism by which DNA damage is induced has not been widely investigated. Recent alterations to the linker chain confirmed BNIP moiety is crucial for activity [20, 21] . Novel modifications to the linker chain, such as, introduction of a bicyclohexylmethane group (bisnaphthalimidopropyl diaminocyclohexylmethane; BNIPDaCHM) ( Fig. 1.) -reduced the flexibility of the linker -but enhanced cellular uptake and biological activity in vitro against MDA-MB-231 cells [20] . Even though DNA is considered to be intrinsic to bisnaphthalimide derivative efficacy as observed in colon cancer cells [8, 22, 23, 24] ;
the relationship between bisnaphthalimide exposure and DNA stability in BC cells, particularly TNBC cells, has not been widely investigated. 6 This study aims to investigate, for the first time, the effect of BNIPDaCHM on DNA stability and repair, as well as, cell cycle modulation in one of the most commonly studied TNBC cell line (i.e., MDA-MB-231 cells) in vitro. These cells were selected to extend our previous work [20] and, also because the treatment of TNBC is associated with poor outcome and still lacks the benefit of targeted therapy.
Therefore, treatment of TNBC is a significant clinical problem for which there is currently not an effective treatment option and so, investigating the effect of a potentially promising anti-cancer derivative in a TNBC cell line may address an important area of cancer research.
Materials and Methods

Materials
All chemicals and cell culture reagents were purchased from Sigma-Aldrich Ltd (Poole, UK) unless otherwise stated. Sterile, disposable cell culture plastics were obtained from Nunc (Fisher ThermoScientific, Loughborough, UK). BNIPDaCHM was synthesised and characterised as reported in Barron et al. [20] . Stock BNIPDaCHM (10 mM) was prepared in 50% (v/v) dimethyl sulfoxide (DMSO), stored at 4°C and diluted to the desired final concentrations in growth media containing serum.
Cell culture
Human breast epithelial MDA-MB-231 cancer cells were purchased from the 
Cytotoxicity -MTT assay
BNIPDaCHM cytotoxicity was quantified using the standard colourimetric 3- 
Detection of apoptosis -Flow cytometry
Detection as a normal breast cell line control. Cells were collected using trypsin and DNA damage assessed using single-cell gel electrophoresis (SCGE; Comet assay) under alkaline conditions as previously described by Singh et al. [26] and further adapted in
Dance et al. [16] and Ralton et al. [19] . Quantification of DNA strand breaks was Expression of human p53, human p21 Waf1/Cip1 and β-actin (Table 1) Hempstead, UK).
Statistics
Unless otherwise stated, each data set contained a minimum of two independent experiments, in which each experiment was comprised of at least 3 was considered to be statistically significant.
Results
BNIPDaCHM treatment reduced cell viability
The cytotoxicity of BNIPDaCHM (0.01-40 µM) was investigated in MDA-MB-231 cells over 72 hours and quantified using the MTT assay (Fig. 2) , where mitochondrial activity is assumed to reflect the rate of cell metabolism and, thus, the rate of enzymatic conversion is directly representative of cell viability. The 46 and 60% after 24, 48 and 72 hours, respectively (Fig. 2) . The IC50 values were 6.8, 5.2 and 4.6 µM after 24, 48 and 72 hours, respectively (Table 2) .
From these results, ≤ 5 µM BNIPDaCHM concentrations were used in all subsequent experiments in this study.
BNIPDaCHM treatment induces cell cycle instability and a loss of plasma membrane integrity
As increased proliferation is a characteristic common to tumour cells, which are more susceptible to cell cycle modulation, the effects of BNIPDaCHM treatment on the cell cycle of MDA-MB-231 cells was investigated using flow cytometry and PI staining (Figs. 3 and 4) . PI is a DNA intercalator that can bind to DNA specifically following the loss of plasma membrane integrity; with the amount of PI proportional to DNA content, which indicates the distribution of cells within the different cell cycle phases (Fig. 3A) .
BNIPDaCHM (5 µM) treatment significantly increased (31%) the sub-G1 population (i.e., cells with low DNA content) and induced a significant decrease (22% and 8%) in the proportion of MDA-MB-231 cells in G1 and G2/M, respectively, compared to the control (DMSO-treated cells) (Fig. 3B) . Cells in S phase were decreased, but not significantly, when compared to control cells (Fig. 3B) . Treatment with etoposide (10 µM; positive control) increased (17%), the sub-G1 population but, not to the same extent as BNIPDaCHM. Also, cell arrest in S phase (8% increase) was observed. Thus, BNIPDaCHM and etoposide use differential mechanisms of action (Fig. 3B ).
Cell cycle checkpoints represent an intersection of cell survival and death
where conditions for successful interphase and mitosis have to be favourable for complete cell division or cell death is triggered. In accordance with this and the finding that BNIPDaCHM increased the cell population in sub-G1; apoptosis was examined by fluorescence microscopy and flow cytometry to further determine the effects of BNIPDaCHM on early cell death in MDA-MB-231 cells (Fig. 4) . Fig. 4B and 4C ). However, a trend for increased annexin V-FITC and 7-AAD labelling in cells treated with BNIPDaCHM indicated a loss of plasma membrane integrity (Fig. 4C) . These results correlate with the AO/EtBr staining observational study (Fig. 4A ) but, no significant differences were observed. with BNIPDaCHM for up to 4 hours revealed no alteration in p53 mRNA levels (Fig. 6A ). However, a significant time dependent increase (25%) in p21 Waf/Cip1 mRNA levels was observed (Fig. 6B) , suggesting that BNIPDaCHM treatment modulates DNA damage independently from p53.
Cell cycle instability is associated with activation of DNA strand breakage
Discussion
In this study, the mechanism of action of a novel bisnaphthalimidopropyl derivative, BNIPDaCHM, was investigated in one of the most commonly studied poly(ADP-ribose) polymerase inhibitors [32] , and also, propolis and its derivative caffeic acid phenethyl ester [33] , to name a few.
This present study delineates the underlying mechanisms utilised by BNIPDaCHM. A significant decrease in cell viability in a concentration (≥ 5 µM) and time (≥ 24 hours) dependent manner were observed. The mechanism of growth inhibition observed after treatment with BNIPDaCHM involved significant DNA strand breaks; identified for the first time to be DSBs observed by the increased expression of γ-H2AX-foci: a specific and sensitive surrogate marker for DNA DSBs [34] . Moreover, treatment with non-genotoxic concentrations of BNIPDaCHM induced a significant decrease in the repair of DNA strand breaks induced by H2O2.
Also, an increase in the sub-G1 cell population (i.e., DNA fragmentation) corroborated the visual changes to cell morphology and plasma membrane integrity/permeability observed with BNIPDaCHM which indicated cell death.. Thus, interestingly, BNIPDaCHM's time-dependent influence on DNA repair capacity has identified a novel mechanism of action for bisnaphthalimide derivatives in a TNBC cell line. Also, BNIPDaCHM treatment resulted in p53-independent expression of p21 Waf1/Cip1 suggesting that the requirement of p53 activation was not essential for BNIPDaCHM cytotoxicity: significant treatment effects were observed in a cell line with mutant p53. This study has shown the specific mechanism of action utilised by a bisnaphthalimidopropyl derivative in MDA-MB-231 cells and, has therefore identified a potentially novel anti-cancer agent.
Induction of cell cycle instability occurs in response to various stresses, including DNA damage. It is well known that cells have an inherent ability to effectively remove and repair DNA damage but, if repair mechanisms in the cell are faulty or the cell is overwhelmed by damage, chances are that the cells will be unable to repair and the damaged cell will be removed by apoptosis. DNA DSB damage directly induced by BNIPDaCHM is the key component in the toxicity of BNIPDaCHM in MDA-MB-231 cells. This mechanism is also consistent with other novel naphthalimide [35] and bisnaphthalimide derivatives [16, 24] .
Finally, previous research has focused on the vital role of p53 in the mechanism of novel naphthalimide derivatives in p53 wild-type cancer cells [36, 37] ; however, to the author's best knowledge, no research is available to reveal the mechanism(s) of the anti-cancer effect of bisnaphthalimide derivatives, particularly in mutant p53 cancer cells. Common in tumours is the generation of non-functional phenotypes which occur by mutations in p53 [38] and, although the frequency of mutations is lower in breast tumours than in other tumour types, mutant status can be positively associated with disease aggressiveness and overall tumour cell survival [39, 40] . It is therefore important that anti-cancer drugs are developed that can specifically target cells independent of their p53 status. This effect was observed for
BNIPDaCHM in MDA-MB-231 breast cancer cells, which have a mutant, nonfunctional form of p53; with significant cytotoxicity and cell death. It has also been shown that, in response to DNA damage, MDA-MB-231 cells undergo increased p53-independent expression of p21 Waf1/Cip1 and altered DNA repair capacity. The elevation of p21 Waf1/Cip1 expression through p53-independent pathways is not a new concept as it has been described in various cell types [41, 42] . However, this proposed mechanism of action is novel for a bisnaphthalimide derivative and thus, offers a significant therapeutic option for tumours with mutant p53, which is the direct cause of resistance to chemotherapy.
In 
